1. Home
  2. FCF vs SNDX Comparison

FCF vs SNDX Comparison

Compare FCF & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Commonwealth Financial Corporation

FCF

First Commonwealth Financial Corporation

HOLD

Current Price

$18.56

Market Cap

1.9B

Sector

Finance

ML Signal

HOLD

Logo Syndax Pharmaceuticals Inc.

SNDX

Syndax Pharmaceuticals Inc.

HOLD

Current Price

$21.75

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FCF
SNDX
Founded
1934
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.8B
IPO Year
1994
2014

Fundamental Metrics

Financial Performance
Metric
FCF
SNDX
Price
$18.56
$21.75
Analyst Decision
Buy
Strong Buy
Analyst Count
4
13
Target Price
$19.75
$38.69
AVG Volume (30 Days)
627.6K
1.5M
Earning Date
04-28-2026
04-30-2026
Dividend Yield
2.94%
N/A
EPS Growth
5.76
11.56
EPS
1.47
N/A
Revenue
N/A
$172,352,000.00
Revenue This Year
$16.32
$107.19
Revenue Next Year
$6.25
$41.88
P/E Ratio
$12.66
N/A
Revenue Growth
N/A
627.84
52 Week Low
$15.00
$8.59
52 Week High
$19.14
$25.59

Technical Indicators

Market Signals
Indicator
FCF
SNDX
Relative Strength Index (RSI) 55.04 48.16
Support Level $18.11 $19.35
Resistance Level $19.05 $22.33
Average True Range (ATR) 0.32 1.11
MACD -0.05 -0.05
Stochastic Oscillator 48.48 54.05

Price Performance

Historical Comparison
FCF
SNDX

About FCF First Commonwealth Financial Corporation

First Commonwealth Financial Corp functions in the financial services sector in the United States. Through its subsidiary, it offers a range of consumer and commercial banking services such as personal checking accounts, interest-earning checking accounts, savings accounts, insured money market accounts, investment certificates, fixed & variable rate certificates of deposit, and various kinds of loans. It also provides trust and wealth management services and offers insurance products. The company earns the majority of its revenue through net interest income.

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Share on Social Networks: